Biogen Idec increased its takeover bid for Facet Biotech by 21% to $17.50 per share. The increase "represents our best-and-final offer to bring this to conclusion," Biogen CEO James Mullen said in a letter to shareholders.
Published in Brief:
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
|Director of Clinical Research||
Regenesis Biomedical, Inc.
Meridian Health Plan
|Assistant Vice President - Dental Director||